HRP20120202T1 - AMIDOFENOKSIINDAZOLI, KORISNI KAO INHIBITORI c-MET - Google Patents
AMIDOFENOKSIINDAZOLI, KORISNI KAO INHIBITORI c-MET Download PDFInfo
- Publication number
- HRP20120202T1 HRP20120202T1 HR20120202T HRP20120202T HRP20120202T1 HR P20120202 T1 HRP20120202 T1 HR P20120202T1 HR 20120202 T HR20120202 T HR 20120202T HR P20120202 T HRP20120202 T HR P20120202T HR P20120202 T1 HRP20120202 T1 HR P20120202T1
- Authority
- HR
- Croatia
- Prior art keywords
- pharmaceutically acceptable
- acceptable salt
- methyl
- compound according
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8329408P | 2008-07-24 | 2008-07-24 | |
| US8508208P | 2008-07-31 | 2008-07-31 | |
| US10865908P | 2008-10-27 | 2008-10-27 | |
| PCT/US2009/050640 WO2010011538A1 (en) | 2008-07-24 | 2009-07-15 | Amidophenoxyindazoles useful as inhibitors of c-met |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20120202T1 true HRP20120202T1 (hr) | 2012-03-31 |
Family
ID=41010247
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20120202T HRP20120202T1 (hr) | 2008-07-24 | 2009-07-15 | AMIDOFENOKSIINDAZOLI, KORISNI KAO INHIBITORI c-MET |
Country Status (35)
| Country | Link |
|---|---|
| US (2) | US8030302B2 (da) |
| EP (1) | EP2310382B1 (da) |
| JP (1) | JP5414794B2 (da) |
| KR (1) | KR101334456B1 (da) |
| CN (1) | CN102105462B (da) |
| AR (1) | AR074632A1 (da) |
| AT (1) | ATE546444T1 (da) |
| AU (1) | AU2009274256B2 (da) |
| BR (1) | BRPI0916286B8 (da) |
| CA (1) | CA2731773C (da) |
| CL (1) | CL2011000134A1 (da) |
| CO (1) | CO6351737A2 (da) |
| CR (1) | CR20110046A (da) |
| CY (1) | CY1112595T1 (da) |
| DK (1) | DK2310382T3 (da) |
| DO (1) | DOP2011000009A (da) |
| EA (1) | EA018385B1 (da) |
| EC (1) | ECSP11010778A (da) |
| ES (1) | ES2379587T3 (da) |
| HR (1) | HRP20120202T1 (da) |
| IL (1) | IL210490A (da) |
| JO (1) | JO2788B1 (da) |
| MA (1) | MA32594B1 (da) |
| MX (1) | MX2011000925A (da) |
| MY (1) | MY163852A (da) |
| NZ (1) | NZ590013A (da) |
| PE (1) | PE20110150A1 (da) |
| PL (1) | PL2310382T3 (da) |
| PT (1) | PT2310382E (da) |
| RS (1) | RS52261B (da) |
| SI (1) | SI2310382T1 (da) |
| SV (1) | SV2011003816A (da) |
| TW (1) | TWI365185B (da) |
| WO (1) | WO2010011538A1 (da) |
| ZA (1) | ZA201100219B (da) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2599458T3 (es) | 2008-10-14 | 2017-02-01 | Sunshine Lake Pharma Co., Ltd. | Compuestos y métodos de uso |
| EP2408300B1 (en) | 2009-03-21 | 2016-05-11 | Sunshine Lake Pharma Co., Ltd. | Amino ester derivatives, salts thereof and methods of use |
| RU2568258C2 (ru) | 2011-02-28 | 2015-11-20 | Саншайн Лейк Фарма Ко., Лтд | Замещенные соединения хинолина и способы их использования |
| US8962623B2 (en) * | 2011-03-04 | 2015-02-24 | Locus Pharmaceuticals, Inc. | Aminopyrazine compounds |
| KR20130118612A (ko) * | 2012-04-20 | 2013-10-30 | (주)네오믹스 | 신규한 아미노피리딘 유도체 및 이의 용도 |
| WO2013169532A1 (en) * | 2012-05-09 | 2013-11-14 | Eli Lilly And Company | Anti-c-met antibodies |
| WO2014134313A1 (en) * | 2013-02-27 | 2014-09-04 | Array Biopharma Inc. | Intermediates for use in the preparation of indazole derivatives and processes for the preparation thereof |
| CN104140393B (zh) * | 2013-12-10 | 2016-09-21 | 郑州泰基鸿诺医药股份有限公司 | 一种芳环/芳杂环叔丁醇酯类化合物的制备方法 |
| US20150299219A1 (en) | 2014-04-22 | 2015-10-22 | Calitor Sciences, Llc | Bicyclic pyrazolone compounds and methods of use |
| TW201716085A (zh) * | 2015-08-12 | 2017-05-16 | 應克隆公司 | 癌症之組合療法 |
| US20190336599A1 (en) * | 2016-04-15 | 2019-11-07 | Eli Lilly And Company | Combination of ramucirumab and merestinib for use in treatment of colorectal cancer |
| US11827688B2 (en) | 2016-06-02 | 2023-11-28 | Immunocore Limited | Dosing regimen for GP100-specific TCR—anti-CD3 SCFV fusion protein |
| WO2018022438A1 (en) * | 2016-07-29 | 2018-02-01 | Eli Lilly And Company | Combination therapy with merestinib and anti-pd-l1 or anti-pd-1 inhibitors for use in the treatment of cancer |
| CN108069938A (zh) * | 2016-11-15 | 2018-05-25 | 中国药科大学 | 2,4-二取代吡啶类化合物及其制备方法和应用 |
| JP6709340B2 (ja) | 2016-11-16 | 2020-06-10 | イーライ リリー アンド カンパニー | エクソン１４スキッピング変異（複数可）またはエクソン１４スキッピング表現型を有するがんの併用療法 |
| WO2018093654A1 (en) | 2016-11-16 | 2018-05-24 | Eli Lilly And Company | Treatment of cancer with exon 14 skipping mutation(s) or exon 14 skipping phenotype |
| CN107311983A (zh) * | 2017-07-06 | 2017-11-03 | 北京万全德众医药生物技术有限公司 | 吲哚类小分子c‑met抑制剂 |
| CN107382968A (zh) * | 2017-07-06 | 2017-11-24 | 北京万全德众医药生物技术有限公司 | 一种吲哚类c‑Met抑制剂的制备方法 |
| US10180422B1 (en) | 2017-08-22 | 2019-01-15 | Scripps Health | Methods of treating a neuroendocrine tumor |
| EP3480201A1 (en) | 2017-11-06 | 2019-05-08 | Oncostellae, S.L. | New analogs as androgen receptor and glucocorticoid receptor modulators |
| US11623923B2 (en) | 2017-11-24 | 2023-04-11 | Medshine Discovery, Inc. | Uracil compound as c-MET/AXL inhibitor |
| US20210177828A1 (en) * | 2018-01-17 | 2021-06-17 | Nanjing Transthera Biosciences Co., Ltd. | Tam family kinase /and csf1r kinase inhibitor and use thereof |
| WO2019182274A1 (en) | 2018-03-08 | 2019-09-26 | Wellmarker Bio Co., Ltd. | Thienopyridine derivatives and pharmaceutical composition comprising same |
| ES2985569T3 (es) * | 2018-08-24 | 2024-11-06 | Transthera Sciences Nanjing Inc | Nuevo inhibidor de derivado de quinolina |
| JP7443373B2 (ja) * | 2018-09-03 | 2024-03-05 | タイリガンド バイオサイエンス（シャンハイ）リミテッド | 抗がん性薬物としてのｔｒｋ阻害剤 |
| EP3819300A4 (en) | 2019-09-06 | 2021-11-24 | Wellmarker Bio Co., Ltd. | THERAPEUTIC COMPOSITION BASED ON BIOMARKERS |
| KR20220170766A (ko) * | 2021-06-22 | 2022-12-30 | 주식회사 엘지화학 | 단백질 키나아제 억제제로서의 신규한 화합물 |
| WO2023110936A1 (en) | 2021-12-14 | 2023-06-22 | Netherlands Translational Research Center Holding B.V | Reversible macrocyclic kinase inhibitors |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NO155316C (no) * | 1982-04-23 | 1987-03-11 | Sintef | Fremgangsmaate for fremstilling av magnetiske polymerpartikler. |
| US5484681A (en) * | 1994-10-31 | 1996-01-16 | Xerox Corporation | Conductive composite particles and processes for the preparation thereof |
| IL114149A0 (en) * | 1995-06-14 | 1995-10-31 | Yeda Res & Dev | Modified avidin and streptavidin molecules and use thereof |
| US5747577A (en) * | 1995-12-27 | 1998-05-05 | Xerox Corporation | Conductive particles containing carbon black and processes for the preparation thereof |
| DE10046029A1 (de) | 2000-09-18 | 2002-03-28 | Bayer Ag | Indazole |
| ES2268015T3 (es) * | 2001-05-18 | 2007-03-16 | Srl, Inc. | Procedimiento de inmunoensayo. |
| US6956084B2 (en) * | 2001-10-04 | 2005-10-18 | Bridgestone Corporation | Nano-particle preparation and applications |
| JP2004067703A (ja) * | 2002-04-24 | 2004-03-04 | Japan Science & Technology Corp | 架橋ポリマー、微粒子および製造方法 |
| US7192780B2 (en) * | 2002-10-23 | 2007-03-20 | Evident Technologies | Fluorescent lifetime biological detection and imaging using water-stable semiconductor nanocrystals |
| ES2273047T3 (es) | 2002-10-28 | 2007-05-01 | Bayer Healthcare Ag | Fenilaminopirimidinas sustituidas con heteroariloxi como inhibidores de rho-cinasa. |
| US6986913B2 (en) * | 2003-07-17 | 2006-01-17 | Dynal Biotech Asa | Process |
| US7163998B2 (en) * | 2003-09-09 | 2007-01-16 | Eastman Kodak Company | Stabilized polymer beads and method of preparation |
| US7173031B2 (en) * | 2004-06-28 | 2007-02-06 | Bristol-Myers Squibb Company | Pyrrolotriazine kinase inhibitors |
| US7439246B2 (en) * | 2004-06-28 | 2008-10-21 | Bristol-Myers Squibb Company | Fused heterocyclic kinase inhibitors |
| JO2787B1 (en) | 2005-04-27 | 2014-03-15 | امجين إنك, | Alternative amide derivatives and methods of use |
| HRP20170103T1 (hr) | 2005-12-21 | 2017-03-24 | Janssen Pharmaceutica N.V. | Triazolopiridazini kao modulatori tirozin kinaze |
| WO2007103308A2 (en) * | 2006-03-07 | 2007-09-13 | Array Biopharma Inc. | Heterobicyclic pyrazole compounds and methods of use |
| EP2038320B1 (en) * | 2006-06-29 | 2014-03-12 | Life Technologies AS | Particles containing multi- block polymers |
| PE20080403A1 (es) | 2006-07-14 | 2008-04-25 | Amgen Inc | Derivados heterociclicos fusionados y metodos de uso |
| BRPI0717320A2 (pt) | 2006-10-23 | 2013-10-22 | Sgx Pharmaceuticals Inc | Triazóis bicíclicos como moduladores de proteína cinase |
| KR101550250B1 (ko) | 2007-06-27 | 2015-09-04 | 알케마 인코포레이티드 | 하이드로플루오로올레핀의 제조 방법 |
-
2009
- 2009-07-10 TW TW098123519A patent/TWI365185B/zh not_active IP Right Cessation
- 2009-07-12 JO JO2009256A patent/JO2788B1/en active
- 2009-07-13 AR ARP090102636A patent/AR074632A1/es active IP Right Grant
- 2009-07-15 RS RS20120176A patent/RS52261B/sr unknown
- 2009-07-15 WO PCT/US2009/050640 patent/WO2010011538A1/en not_active Ceased
- 2009-07-15 MY MYPI2011000343A patent/MY163852A/en unknown
- 2009-07-15 PT PT09790440T patent/PT2310382E/pt unknown
- 2009-07-15 CA CA2731773A patent/CA2731773C/en not_active Expired - Fee Related
- 2009-07-15 NZ NZ590013A patent/NZ590013A/en not_active IP Right Cessation
- 2009-07-15 AU AU2009274256A patent/AU2009274256B2/en not_active Ceased
- 2009-07-15 ES ES09790440T patent/ES2379587T3/es active Active
- 2009-07-15 PL PL09790440T patent/PL2310382T3/pl unknown
- 2009-07-15 EP EP09790440A patent/EP2310382B1/en active Active
- 2009-07-15 EA EA201170252A patent/EA018385B1/ru not_active IP Right Cessation
- 2009-07-15 PE PE2011000061A patent/PE20110150A1/es active IP Right Grant
- 2009-07-15 MX MX2011000925A patent/MX2011000925A/es active IP Right Grant
- 2009-07-15 JP JP2011520095A patent/JP5414794B2/ja not_active Expired - Fee Related
- 2009-07-15 CN CN200980128694.4A patent/CN102105462B/zh not_active Expired - Fee Related
- 2009-07-15 KR KR1020117001628A patent/KR101334456B1/ko not_active Expired - Fee Related
- 2009-07-15 DK DK09790440.3T patent/DK2310382T3/da active
- 2009-07-15 BR BRPI0916286A patent/BRPI0916286B8/pt not_active IP Right Cessation
- 2009-07-15 AT AT09790440T patent/ATE546444T1/de active
- 2009-07-15 US US12/503,223 patent/US8030302B2/en not_active Ceased
- 2009-07-15 HR HR20120202T patent/HRP20120202T1/hr unknown
- 2009-07-15 SI SI200930193T patent/SI2310382T1/sl unknown
-
2011
- 2011-01-06 IL IL210490A patent/IL210490A/en active IP Right Grant
- 2011-01-07 ZA ZA2011/00219A patent/ZA201100219B/en unknown
- 2011-01-07 DO DO2011000009A patent/DOP2011000009A/es unknown
- 2011-01-19 CO CO11005437A patent/CO6351737A2/es not_active Application Discontinuation
- 2011-01-21 EC EC2011010778A patent/ECSP11010778A/es unknown
- 2011-01-21 SV SV2011003816A patent/SV2011003816A/es active IP Right Grant
- 2011-01-21 CL CL2011000134A patent/CL2011000134A1/es unknown
- 2011-01-24 CR CR20110046A patent/CR20110046A/es unknown
- 2011-01-24 MA MA33555A patent/MA32594B1/fr unknown
- 2011-12-08 US US13/374,053 patent/USRE43878E1/en not_active Expired - Fee Related
-
2012
- 2012-04-04 CY CY20121100337T patent/CY1112595T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20120202T1 (hr) | AMIDOFENOKSIINDAZOLI, KORISNI KAO INHIBITORI c-MET | |
| JP2011529054A5 (da) | ||
| HRP20210949T1 (hr) | Spojevi i sastavi za moduliranje aktivnosti egfr mutant kinaze | |
| JP2014508811A5 (da) | ||
| JP2021523221A5 (da) | ||
| JP2015512435A5 (da) | ||
| UA115881C2 (uk) | Алкоксипіразоли як активатори розчинної гуанілатциклази | |
| JP2015518894A5 (da) | ||
| ME02684B (me) | Jedinjenja i preparati protein kinaznih inhibitora | |
| JP2016506369A5 (da) | ||
| PH12018500106A1 (en) | Ethynyl derivatives as metabotropic glutamate receptor modulators | |
| HRP20170352T1 (hr) | Spojevi bis(fluroalkil)-1,4-benzodiazepinona kao notch inhibitori | |
| MD20140084A2 (en) | New indolizine derivatives, method for preparing same and pharmaceutical compositions containing same | |
| HRP20210291T1 (hr) | Imunoregulatorna sredstva | |
| EA201491671A1 (ru) | Гетероциклильные соединения | |
| NZ607638A (en) | Novel compounds and compositions for the inhibition of nampt | |
| JP2015537020A5 (da) | ||
| RU2015121424A (ru) | Комбинированная терапия | |
| JP2013505969A5 (da) | ||
| CY1115175T1 (el) | Ενωσεις 9-υποκατεστημενης-8-οξο-αδενινης ως ρυθμιστες υποδοχεων τυπου toll (tlr7) | |
| JP2014506907A5 (da) | ||
| JP2016506960A5 (da) | ||
| JP2013525458A5 (da) | ||
| JP2013534245A5 (da) | ||
| JP2016501185A5 (da) |